- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05180279
The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis
July 31, 2025 updated by: Ali Keshavarzian, Rush University Medical Center
The purpose of this study is to investigate if circadian malalignment (unusual sleeping patterns), such as night shifts (sleeping during the day and being awake during the night time), worsens the inflammation of the gut.
We hope to look at patients with Ulcerative Colitis and Healthy Controls.
Study Overview
Study Type
Interventional
Enrollment (Actual)
19
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
UC patients:
- M/F, 18-50 y/o
- Inactive Disease (Mayo Score ≤ 2)
- Stable medications with no disease flares for the > 3 months
- Left-sided UC (Montreal E1 or E2)
- Normal psychological evaluation and negative drug screen (See Below)
Healthy Controls:
- M/F, 18-50 y/o, age ± 3y sex, race, and BMI match with UC subject
- No clinical evidence of any medical illness
- Normal psychological evaluation and negative drug screen (See Below)
Exclusion Criteria:
UC patients:
- Patients with other forms of colitis such as Crohn's disease (CD) or indeterminate colitis
- Patient with active UC (Mayo > 2)
- Pancolonic UC (colitis past the splenic flexure, Montreal E3))
- Use of biologic or immunomodulatory medications (i.e. Infliximab, Adalimumab, azathioprine, Vedolizumab, methotrexate, etc.)
- Gastrointestinal surgery
- Other GI diseases or systemic diseases (cardiac, renal failure, cirrhosis)
- Shift work in the last 6 months
- Antibiotic use within last 12 weeks
- Patients who have used anti-diarrheal agents such as Lomotil or Imodium within 3 days of the study
- Prednisone use the last 30 days
- Significant Depression (score ≥ 14 BDI)
- Significant Anxiety (score ≥ 40 STAI)
- Use of probiotic supplement in last 4 weeks except yogurt.
- Intentional change in diet.
- Chronic use of NSAIDS. A washout period of 3 weeks is needed before the subject could be enrolled into the study. Low dose aspirin is allowed.
- Chronic Alcohol use. A washout period of 3 weeks is needed before the subject could be enrolled into the study.
- Have children under 6 months
Healthy Controls:
- History of drug abuse, gastrointestinal (GI) surgery, GI diseases, or systemic diseases such as renal (creatinine>1.2 mg/dl), liver, cardiac, or diabetes (Hgb-A1c>8%)
- Antibiotic use within last 12 weeks
- Shift work in the last 6 months
- Use of probiotic supplement except yogurt in last 4 weeks.
- Atypical American diet with daily fiber ≥ 16 grams or daily saturated fat ≤ 11 grams by Food Frequency Questionnaire
- Chronic use of NSAIDS. A washout period of 3 weeks is needed before the subject could be enrolled into the study.
- Chronic Alcohol use. A washout period of 3 weeks is needed before the subject could be enrolled into the study.
- Significant Depression (score ≥ 14 BDI)
- Significant Anxiety (score ≥ 40 STAI)
- Regular use of medications that affect intestinal permeability, intestinal motility and/or endogenous melatonin including metoclopramide, NSAIDs, antibiotics, beta blocker, psychotropic medication, hypnotics and exogenous melatonin products during 4 weeks prior to the study
- People who crossed more than 2 time zones in the previous month
- Inability to sign an informed consent form.
- Have children under 6 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Sleep Lab
|
Patients will stay in 7-day sleep lab where light exposure, diet, and activity will be closely monitored.
They will have two unprepped flexible sigmoidoscopies with rectal biopsy collection and stool collection.
Cycles will be shifted by 12h once on Day 3 of sleep lab and be discharged after an 8 hour sleep session on Day 7.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Dim Light Melatonin Onset (DLMO) From Baseline (Aligned) to Circadian Misalignment Misalignment
Time Frame: Blood is drawn every hour over 8 hours to measure plasma melatonin in dim light < 5 lux in Aligned Circadian Rhythms, and blood is drawn every hour for 12 hours under dim light in Misaligned Circadian rhythms.
|
Amount of time between dim light melatonin onset (DLMO) to sleep onset.
The hours reported for this outcome measure equates the time of the day the participant fell asleep
|
Blood is drawn every hour over 8 hours to measure plasma melatonin in dim light < 5 lux in Aligned Circadian Rhythms, and blood is drawn every hour for 12 hours under dim light in Misaligned Circadian rhythms.
|
|
Change in Intestinal Permeability From Baseline (Aligned Circadian Rhythms) to Circadian Misalignment
Time Frame: 24 hour urine collection beginning at baseline and 24 hour urine collection at circadian misalignment, an average of 3 days from baseline to circadian misalignment
|
Intestinal permeability is assessed through spectrophotometric measurements of sucralose, sucrose, maltose and lactulose concentrations in urine following ingestion of a sugar cocktail.
|
24 hour urine collection beginning at baseline and 24 hour urine collection at circadian misalignment, an average of 3 days from baseline to circadian misalignment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in 24 Hour Urinary Melatonin Concentrations From Baseline (Aligned Circadian Rhythms) to Circadian Misalignment
Time Frame: 24 hour urine collection at baseline and 24 hour urine collection at circadian misalignment circadian
|
Spectrophotometry
|
24 hour urine collection at baseline and 24 hour urine collection at circadian misalignment circadian
|
|
Change in Mayo Score From Baseline (Aligned Circadian Rhythms) to Circadian Misalignment
Time Frame: 30 minute flexible sigmoidoscopy at Baseline and 30 minute flexible sigmoidoscopy at Circadian Misalignment
|
Within the endoscopic component of the Mayo Score, a score of 0 is given for normal mucosa or inactive UC, while a score of 1 is given for mild disease with evidence of mild friability, reduced vascular pattern, and mucosal erythema.
|
30 minute flexible sigmoidoscopy at Baseline and 30 minute flexible sigmoidoscopy at Circadian Misalignment
|
|
Change in Stool Calprotectin From Baseline (Aligned Circadian Rhythms) to Circadian Misalignment
Time Frame: 10 minute stool collection conducted at baseline circadian rhythm and at circadian misalignment.
|
Calprotectin is a sensitive marker for inflammation in the gastrointestinal tract.
Measured through enzyme linked immunosorbent assay for calprotectin in stool extract.
|
10 minute stool collection conducted at baseline circadian rhythm and at circadian misalignment.
|
|
Change in Concentration of Serum Cytokine Markers of Inflammation From Baseline (Aligned Circadian Rhythms) to Circadian Misalignment
Time Frame: Blood is drawn every two hours over a 24 hour period at baseline (12 draws), and blood is drawn every two hours over a 24 hour period at circadian misalignment
|
Enzyme linked immunosorbent assay
|
Blood is drawn every two hours over a 24 hour period at baseline (12 draws), and blood is drawn every two hours over a 24 hour period at circadian misalignment
|
|
Changes in Clock Gene Expression in Peripheral Blood Mononuclear Cells From Baseline (Aligned Circadian Rhythms) to Circadian Misalignment
Time Frame: Blood is drawn every two hours over a 24 hour period at baseline (12 draws), and blood is drawn every two hours over a 24 hour period at circadian misalignment
|
RNA Sequencing
|
Blood is drawn every two hours over a 24 hour period at baseline (12 draws), and blood is drawn every two hours over a 24 hour period at circadian misalignment
|
|
Changes in Gene Expression of Colonic Tissue Biopsies From Baseline (Aligned Circadian Rhythms) to Circadian Misalignment
Time Frame: 30 minute flexible sigmoidoscopy at Baseline and 30 minute flexible sigmoidoscopy at Circadian Misalignment
|
Tissue biopsies collected during flexible sigmoidoscopy conducted at Baseline Circadian Rhythm and at Circadian Misalignment.
Assessed through histology and RNA Sequencing
|
30 minute flexible sigmoidoscopy at Baseline and 30 minute flexible sigmoidoscopy at Circadian Misalignment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diet
Time Frame: Once before sleep lab
|
Vioscreen Food Frequency Questionnaire (FFQ).
Total of 19 measured food components.
Vioscreen captures comprehensive dietary behaviors in just 30 minutes.
It is a unique dietary questionnaire, management and analysis system that efficiently gathers and manages data that immediately identifies dietary "habits" and counsel for lifestyle changes.
|
Once before sleep lab
|
|
Chronotype
Time Frame: Screening
|
The Munich ChronoType Questionnaire (MCTQ) uses a self-rated scale to assess individual phase of entrainment on work and work-free days; it is a tool to collect primary sleep times, such as bed- and rise-times, plus the clock time of becoming fully awake as well as sleep latency and inertia, in addition to other time points.
|
Screening
|
|
Beck Depression Inventory
Time Frame: 3 Weeks prior to circadian lab assessments
|
The Beck Depression Inventory (BDI, BDI-II), created by Dr. Aaron T. Beck, is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.
|
3 Weeks prior to circadian lab assessments
|
|
Pittsburgh Sleep Quality Index
Time Frame: 3 Weeks prior to circadian lab assessments
|
The following questions relate to your usual sleep habits during the past month only.
|
3 Weeks prior to circadian lab assessments
|
|
Single Day Food Recall
Time Frame: Once before sleep lab
|
Automated Self-Administered 24-Hour Recall (ASA24) Dietary Assessment.
Total nutrients from all supplements reported in a given day.
|
Once before sleep lab
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2021
Primary Completion (Actual)
June 5, 2024
Study Completion (Actual)
June 5, 2024
Study Registration Dates
First Submitted
December 14, 2021
First Submitted That Met QC Criteria
January 2, 2022
First Posted (Actual)
January 6, 2022
Study Record Updates
Last Update Posted (Actual)
August 19, 2025
Last Update Submitted That Met QC Criteria
July 31, 2025
Last Verified
July 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19051402
- R01DK124280 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.